<DOC>
	<DOCNO>NCT01402089</DOCNO>
	<brief_summary>It well know substantial interindividual variability CYP3A4/1A2-phenotype activity important contributor individual difference sensitivity frequently use tyrosine kinase inhibitor sunitinib erlotinib . This study test potential CYP-phenotyping predict individual pharmacology derive dosing algorithm tailor treatment drug .</brief_summary>
	<brief_title>Cytochrom p450 3A4 1A2 Phenotyping Individualization Treatment With Sunitinib Erlotinib Cancer Patients</brief_title>
	<detailed_description>Objectives : The primary objective study show individual CYP3A4 CYP1A2-phenotype assess probe drug predict drug exposure sunitinib erlotinib . Secondary objective study define correlation individual CYP-phenotype treatment-related toxicity , test feasibility drug bioanalysis patient 's dry blood spot ( DBS ) , build integrated covariate model sunitinib erlotinib pharmacokinetics define dose algorithm sunitinib erlotinib base individual CYP-phenotype . Study endpoint : Primary endpoint : • To show individual drug clearance sunitinib erlotinib significantly high patient high-activity CYP3A4/1A2-phenotype . Secondary endpoint : - To specify correlation CYP-phenotype treatment-related toxicity . - To assess feasibility drug bioanalysis patient 's dry blood spot ( DBS ) . - To build integrated covariate model sunitinib erlotinib pharmacokinetics define quantitative relationship CYP-phenotype activity drug exposure . - To define dose algorithm sunitinib erlotinib base individual CYP-phenotype use data simulation previously define population covariate model . Trial Design : Prospective , nonrandomized , pharmacological cohort study . Main selection criterion - Histologically cytologically confirm renal-cell cancer ( sunitinib ) , gastrointestinal stromal tumor ( sunitinib ) non small-cell lung cancer ( erlotinib ) - Both early advanced tumor stage - Indication therapeutic use either sunitinib erlotinib - Written inform consent willing undergo PK-sampling - Adequate organ function - No concurrent radiotherapy systemic anticancer treatment another drug Trial Duration The present study project start June 2011 , inclusion total 60 patient ( least 25 patient sunitinib erlotinib ) . The study expect finalize patient accrual December 2013 . Statistical consideration The trial design show linear inverse relationship individual CYP-phenotype total drug steady-state AUC ( sunitinib plus SU12662 erlotinib plus OSI-420 , respectively ) , whereat CYP1A2 account metabolism erlotinib . With inclusion 60 patient , study power 90 % detect relevant relationship CYP-phenotype activity sunitinib/erlotinib steady-state AUC , regression coefficient &gt; 0.4 H1-hypothesis ( accept regression coefficient &gt; 0.1 H0-hypothesis ) 5 % significance level . Trial Treatment Sunitinib : 50 mg p.o . daily 4 6 week , 37.5 mg daily continuous disease progression , unacceptable toxicity withdrawal inform consent . Erlotinib : 150 mg p.o . daily disease progression , unacceptable toxicity withdrawal inform consent . Potential study outcome This study make significant contribution global effort individualized anticancer treatment . If successful , able make dose recommendation sunitinib erlotinib base simple probe drug assay .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Histologically cytologically confirm renalcell cancer gastrointestinal stromal tumor ( sunitinib ) non smallcell lung cancer ( erlotinib ) Both early advanced tumor stage Indication therapeutic use either sunitinib erlotinib Written inform consent willing undergo PKsampling Patients &gt; 18 year age ECOG performance status ≤2 Adequate laboratory parameter : i. Serum creatinine serum bilirubin ≤ 1.5 X ULN ii . Serum ALT AST ≤ 2.5 X ULN ( ≤ 5 case liver metastasis ) iii . Serum calcium ≤ 11,6 mg/dl ( 2.9 mmol/L ) Previous treatment sunitinib erlotinib Known hypersensitivity trial drug compound drug Concurrent radiotherapy Concurrent systemic anticancer treatment exception bisphosphonates bevacizumab patient non smallcell lung cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>phenotyping</keyword>
	<keyword>cytochrome p450</keyword>
	<keyword>erlotinib</keyword>
	<keyword>sunitinib</keyword>
	<keyword>lung cancer</keyword>
	<keyword>renal-cell cancer</keyword>
	<keyword>gastrointestinal stromal tumor</keyword>
</DOC>